CSL's RiaSTAP approved in US for fibrinogen deficiency
This article was originally published in Scrip
Executive Summary
The US FDA has granted accelerated approval of CSL Behring's clotting agent RiaSTAP (fibrinogen concentrate (human)) for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, an orphan indication that affects 150-300 people in the US.